Search

Astellas Pharma Inc.
  • Top MenuAbout
    • Philosophy
    • Vision & Strategy
    • Group Code of Conduct
    • Astellas Pharma Israel
    • Policies & Position Statements
    • Ethics & Compliance
    • Transparency
    • Making an Impact
    • Support for Medical Education
  • Top MenuTherapy Areas
    • Therapy Areas
      • Urology
      • Oncology / Haematology
      • Transplantation
      • Women’s Health
    • Astellas Products
      • BETMIGA™ (mirabegron)
      • XTANDI™ (enzalutamide)
      • XOSPATA™ (gilteritinib)
      • ADVAGRAF™ (tacrolimus prolonged release)
      • PROGRAF™ (tacrolimus)
      • PADCEV™ (enfortumab vedotin)
      • VEOZA™ (fezolinetant)
  • Top MenuInnovation
    Clinical Trials
    Astellas has established a website to disclose information obtained from Astellas-sponsored clinical trials…
    לקריאה נוספת
    • R & D
      • Clinical Trials
      • Approach
      • Ethics & Principles
    • Pipeline
    • Investigator Sponsored Research
  • Top MenuSustainability
    Access to Health
    Advances continue to be made in technology and medicine that address unmet medical needs. However, there still remain barriers for many people…
    לקריאה נוספת
    • Global Sustainability Policy
    • Sustainability Approach
    • Access to Health
    • Environment
    • Modern Slavery Act
    • Gender Pay Gap Report
  • Top MenuNews
    Media Contacts
    The Astellas Corporate Communications team will respond to calls and emails from journalists. For general media enquiries, please email contact_uk...
    לקריאה נוספת
    • News
    • Media Contacts
    • Social Media Code of Conduct

Common header menu

  • CONTACT US
  • CAREERS
  • WORLDWIDE
  • ISRAEL
  • WORLDWIDE - ISRAEL
  • English
  • עברית
  1. Home
  2. Therapy Areas
  3. Astellas Products
  4. ADVAGRAF™ (tacrolimus prolonged release)

ADVAGRAF™

Advagraf

Name: Advagraf

  • Active ingredient: Tacrolimus
  • Dosages: 0.5mg, 1mg, 3mg, 5mg
  • For more information:

    https://israeldrugs.health.gov.il/#!/medDetails/153%2007%2034071%2000
    https://israeldrugs.health.gov.il/#!/medDetails/153%2008%2034073%2000
    https://israeldrugs.health.gov.il/#!/medDetails/153%2009%2034074%2000
    https://israeldrugs.health.gov.il/#!/medDetails/153%2010%2034075%2000
    Therapy area Transplantation

Do not replace with another tacrolimus preparation, unless the doctor from the transplant clinic you are treated in approves that.

  • Linkedin
  • Twitter

Therapy Areas

Main navigation

  • Therapy Areas
    • Urology
    • Oncology / Haematology
    • Transplantation
    • Women’s Health
  • Astellas Products
    • BETMIGA™ (mirabegron)
    • XTANDI™ (enzalutamide)
    • XOSPATA™ (gilteritinib)
    • ADVAGRAF™ (tacrolimus prolonged release)
    • PROGRAF™ (tacrolimus)
    • PADCEV™ (enfortumab vedotin)
    • VEOZA™ (fezolinetant)

MAT-IL-NON-2023-00024

LogoSolgan

Follow us on social media

linkedin_icon X logo-white-footer

Bottom footer menu

  • SITE MAP
  • PRIVACY NOTICE
  • TERMS OF USE
  • COOKIES POLICY
© 2024 Astellas Pharma Inc.

Update cookie preference